• 1. Pyrrole: a resourceful small molecule in key medicinal hetero-aromatics
  Varun Bhardwaj,Divya Gumber,Vikrant Abbot,Saurabh Dhiman,Poonam Sharma RSC Adv. 2015 5 15233

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyrimidines Pyrrolo[2,3-d]pyrimidines

Introduction to 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diol (CAS No. 39929-79-8)

7H-Pyrrolo[2,3-d]pyrimidine-2,4-diol, with the CAS number 39929-79-8, is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of pyrrolopyrimidines, which are known for their diverse biological activities and potential therapeutic applications. In this comprehensive introduction, we will delve into the chemical structure, synthesis methods, biological properties, and recent advancements in the research and development of 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diol.

Chemical Structure and Properties

7H-Pyrrolo[2,3-d]pyrimidine-2,4-diol is a heterocyclic compound with a molecular formula of C₉H₈N₄O₂. The molecule consists of a pyrrole ring fused to a pyrimidine ring, with two hydroxyl groups attached at the 2 and 4 positions. This unique structural arrangement confers several important properties to the compound. The presence of multiple nitrogen atoms and hydroxyl groups makes it highly polar and capable of forming hydrogen bonds, which can influence its solubility and reactivity in various solvents.

The molecular weight of 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diol is approximately 196.18 g/mol. It is a white crystalline solid at room temperature and has a melting point ranging from 150°C to 155°C. The compound is stable under normal conditions but may degrade upon exposure to strong acids or bases. Its stability and solubility characteristics make it suitable for various chemical reactions and biological assays.

Synthesis Methods

The synthesis of 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diol has been extensively studied due to its importance in pharmaceutical research. One common method involves the reaction of 1H-pyrrole-2-carbaldehyde with urea or thiourea in the presence of an acid catalyst. This reaction typically proceeds via a condensation step followed by cyclization to form the pyrrolopyrimidine core. Subsequent oxidation steps can introduce the hydroxyl groups at the desired positions.

An alternative synthetic route involves the use of microwave-assisted synthesis, which has gained popularity due to its efficiency and environmental friendliness. Microwave irradiation can significantly reduce reaction times and improve yields by promoting rapid heating and enhanced mass transfer. Recent studies have also explored the use of green chemistry principles in the synthesis of 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diol, focusing on reducing waste generation and minimizing the use of hazardous reagents.

Biological Properties and Applications

7H-Pyrrolo[2,3-d]pyrimidine-2,4-diol exhibits a wide range of biological activities that make it a valuable scaffold for drug discovery. One of its most notable properties is its ability to inhibit various kinases, which are key enzymes involved in cell signaling pathways. Kinase inhibitors have become an important class of drugs for treating cancer and other diseases characterized by aberrant cell growth.

In particular, 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diol has shown promising activity as an inhibitor of Aurora kinases. Aurora kinases play crucial roles in mitosis and are often overexpressed in cancer cells. By inhibiting these kinases, 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diol can disrupt cell division and induce apoptosis in cancer cells. Preclinical studies have demonstrated that this compound can effectively inhibit tumor growth in various cancer models.

Beyond its anticancer potential, 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diol has also been investigated for its anti-inflammatory properties. Inflammatory diseases such as arthritis and inflammatory bowel disease (IBD) are characterized by chronic inflammation mediated by cytokines and other inflammatory mediators. Research has shown that 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diol can modulate the production of pro-inflammatory cytokines and reduce inflammation in animal models.

Clinical Trials and Future Directions

The promising preclinical results with 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diol have led to several clinical trials aimed at evaluating its safety and efficacy in human patients. Early-phase clinical trials have shown that the compound is well-tolerated at therapeutic doses with minimal side effects. These findings have paved the way for further clinical development.

Ongoing research is focused on optimizing the pharmacokinetic properties of 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diol, such as improving its oral bioavailability and extending its half-life in vivo. Additionally, efforts are being made to develop prodrugs or drug delivery systems that can enhance the therapeutic index of this compound.

In conclusion, 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diol (CAS No. 39929-79-8)CAS No. 39929-79-8) is a multifaceted compound with significant potential in pharmaceutical research. Its unique chemical structure confers diverse biological activities that make it an attractive candidate for drug development. Ongoing research continues to uncover new applications and improve its therapeutic profile.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)